PROGNOSTXHEALTH

Serial Number 97542778
606

Registration Progress

Application Filed
Aug 10, 2022
Under Examination
Jan 16, 2024
Approved for Publication
Nov 21, 2023
Published for Opposition
Nov 21, 2023
Registered

Basic Information

Serial Number
97542778
Filing Date
August 10, 2022
Published for Opposition
November 21, 2023
Abandonment Date
February 17, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Feb 17, 2025
Classes
005 009 010 042
+1 more

Rights Holder

PROGNOSTX HEALTH INC.

03
Address
6508 OLD FLOYDSBURG ROAD
SUITE 1, BUILDING 2
PEWEE VALLEY, KY 40056-9116

Ownership History

AmDx PrognostX, Inc.

Original Applicant
03
Pewee Valley, KY

AmDx PrognostX, Inc.

Owner at Publication
03
Pewee Valley, KY

PROGNOSTX HEALTH INC.

New Owner After Publication #1
03
PEWEE VALLEY, KY

Legal Representation

Attorney
Monte L. Falcoff

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

27 events
Date Code Type Description
Feb 17, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 17, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Oct 3, 2024 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 3, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 3, 2024 EX1G S SOU EXTENSION 1 GRANTED
Jul 11, 2024 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 9, 2024 EEXT I SOU TEAS EXTENSION RECEIVED
Jul 9, 2024 EXT1 S SOU EXTENSION 1 FILED
Jan 16, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 5, 2023 DOCK D ASSIGNED TO EXAMINER
Nov 21, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 21, 2023 PUBO A PUBLISHED FOR OPPOSITION
Nov 1, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 13, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 13, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED
Oct 13, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 13, 2023 GNEA O EXAMINERS AMENDMENT E-MAILED
Oct 13, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN
Sep 7, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 6, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 6, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 8, 2023 GNRT F NON-FINAL ACTION E-MAILED
Jun 8, 2023 CNRT R NON-FINAL ACTION WRITTEN
May 30, 2023 DOCK D ASSIGNED TO EXAMINER
Aug 30, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 13, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
diagnostic kits and instruments primarily comprised of immunological assays, antibodies and reagents for medical testing of diseases; testing apparatus and instruments being diagnostic kits for medical or research purposes primarily comprised of reagents for creating assays to capture and detect disease biomarkers
Class 009
Computer hardware, recorded software, and control algorithms sold as a unit for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers including cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder
Class 010
diagnostic kits and instruments primarily comprised of a coated surface, a reagent and an immunoassay using antibodies or molecular probes for medical diagnosis of diseases and medical use; testing apparatus and instruments for medical purposes in the nature of a coated plate or other surface materials including but not limited to plastic, glass, or metals used to create assays to capture and detect disease biomarkers; Medical diagnostic and therapeutic apparatuses primarily comprised of antibody or antigen coated surfaces, reagents, immunoassays, computers, software and algorithms for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers including cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder
Class 042
Biomedical research services; scientific laboratory services; providing reagent sample testing for others in the fields of medical diseases and medicine; Development of testing for kidney diseases in a laboratory setting; Medical and scientific research, namely, conducting clinical trials for others featuring clinical trial design, statistical evaluation, and execution; Scientific and medical research and consulting services featuring algorithms, artificial intelligence and machine learning development, evaluation and clinical utility; Scientific and medical research and consulting services featuring biostatistical support; Manufacturing services, namely, development of minimal viable products in the nature of medical diagnostic tests for others; consulting services related to laboratory developed testing procedures, strategy and execution in the field of medical diagnostics, medical tests and pharmaceutical research; Quality evaluation of clinical utility and applicability of innovative technologies in the medical field
Class 044
Medical diagnostic services relating to diseases; medical testing services relating to the diagnosis and treatment of disease; Medical services, namely, administering reagent-based sample tests for others for diagnosis of diseases; Providing medical diagnostic information services for determining medical risk-scores for prediabetes, diabetes, obesity, kidney disease, cardiovascular disease, hypertension, eye disease, dementia and Alzheimer's disease, neurodevelopmental disorders, and solid organ cancers, cancers of the gastrointestinal tract, kidney, lung, liver, pancreas, and bladder using computers, software and algorithms

Classification

International Classes
005 009 010 042 044